



US007745174B2

(12) **United States Patent**
Kim et al.(10) **Patent No.:** US 7,745,174 B2
(45) **Date of Patent:** *Jun. 29, 2010(54) **HYBRID HEPATOCYTE GROWTH FACTOR GENE HAVING HIGH EXPRESSION EFFICIENCY OF TWO HETEROGENEITIES OF HEPATOCYTE GROWTH FACTOR**(75) Inventors: **Jong-Mook Kim**, Seoul (KR); **Woong Hahn**, Goyang (KR); **Eun-Jin Park**, Seoul (KR)(73) Assignee: **Viromed Co., Ltd.**, Seoul (KR)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **12/650,860**(22) Filed: **Dec. 31, 2009**(65) **Prior Publication Data**

US 2010/0105878 A1 Apr. 29, 2010

Related U.S. Application Data

(63) Continuation of application No. 10/944,277, filed on Sep. 20, 2004, which is a continuation of application No. PCT/KR03/00548, filed on Mar. 20, 2003.

(30) **Foreign Application Priority Data**

Mar. 20, 2002 (KR) 10-2002-0015074

(51) **Int. Cl.****C12P 21/06** (2006.01)
C12P 21/04 (2006.01)
C12N 15/09 (2006.01)(52) **U.S. Cl.** **435/69.1; 435/69.4; 435/70.1; 435/71.1**(58) **Field of Classification Search** None
See application file for complete search history.(56) **References Cited**

U.S. PATENT DOCUMENTS

5,328,836 A	7/1994	Shima et al.
5,500,354 A	3/1996	Kitamura et al.
5,580,859 A	12/1996	Felgner et al.
5,587,359 A	12/1996	Higashio et al.
5,652,225 A	7/1997	Isner
5,693,622 A	12/1997	Wolff et al.
6,013,624 A	1/2000	Goldberg et al.
6,121,246 A	9/2000	Isner
6,248,722 B1	6/2001	Morishita et al.
6,258,787 B1	7/2001	Isner
6,316,419 B1	11/2001	Leiden et al.
6,413,942 B1	7/2002	Felgner et al.
6,498,144 B1	12/2002	Goldberg et al.
6,706,694 B1	3/2004	Wolff et al.
6,887,477 B1	5/2005	Nagano et al.
7,285,540 B2	10/2007	Morishita et al.
2002/0172663 A1	11/2002	Palasis
2003/0148968 A1	8/2003	Hammond et al.
2003/0171287 A1	9/2003	Morishita et al.

2004/0105882 A1	6/2004	Morishita et al.
2004/0228834 A1	11/2004	Isner et al.
2005/0079581 A1	4/2005	Kim et al.
2006/0286072 A1	12/2006	Giordano et al.
2007/0059288 A1	3/2007	Dinsmore et al.
2008/0268030 A1	10/2008	Morishita et al.
2009/0004260 A1	1/2009	Morishita et al.
2009/0082293 A1	3/2009	Giordano et al.
2009/0131350 A1	5/2009	Kim et al.
2009/0202606 A1	8/2009	Kim et al.

FOREIGN PATENT DOCUMENTS

JP	11-246433	9/1999
WO	WO 98/50079 A2	11/1998
WO	WO 99/45775 A1	9/1999
WO	WO 01/34208 A1	5/2001
WO	WO 02/089856 A1	11/2002

OTHER PUBLICATIONS

Deng, et al., "Secretory Expression of the Deleted Variant of Human Hepatocyte Growth Factor (hdHGF) in *Pichia pastoris*," *Chinese Journal of Biochemistry and Molecular Biology*, 2001, 17:590-594, China Academic Journal Electronic Publishing House, Beijing, China.
Kisselev, L., "Polypeptide Release Factors in Prokaryotes and Eukaryotes: Same Function, Different Structure," *Structure*, 2002, 10, pp. 8-9, Elsevier Science Ltd., Cambridge, Massachusetts, USA.
Liu, Y., "The human hepatocyte growth factor receptor gene: complete structural organization and promoter characterization," *Gene* 215:159-169, Elsevier/North-Holland (1998).
Miyazawa, K., et al., "Molecular Cloning and Sequence Analysis of cDNA for Human Hepatocyte Growth Factor," *Biochem. Biophys. Res. Commun.* 163:967-973, Academic Press (1989).
Nakamura, T., et al., "Molecular cloning and expression of human hepatocyte growth factor," *Nature* 342:440-443, Nature Publishing Group (1989).
NCBI Entrez, GenBank Database, Accession No. AC004960, "Homo sapiens PAC clone RP5-1098B1 from 7q11.23-q21, complete sequence," 51 pages (first available 1998).
Ngo et al., In The Protein Folding Problem and Tertiary Structure Prediction, 1994, Merz et al. (ed.), Birkhauser, Boston, MA, pp. 433 and 492-495.
Potrykus. Gene transfer to cereals: an assessment, *Biotechnology*, 1990, 8(6):535-542.
Rubin, et al., "A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor," *Proc. Natl. Acad. Sci. USA*, 1991, 88:415-419, Proceedings of the National Academy of Sciences of the United States of America, 500 5th St., Washington, DC 20001.

(Continued)

Primary Examiner—Suzanne M. Noakes*Assistant Examiner*—Jae W Lee(74) *Attorney, Agent, or Firm*—Sterne, Kessler, Goldstein & Fox P.L.L.C.(57) **ABSTRACT**

The present invention relates to a hybrid Hepatocyte Growth Factor (HGF) gene which is prepared by inserting an inherent or foreign intron between exons 4 and 5 in HGF cDNA, which has a base sequence of SEQ ID NO: 2. The gene has high expression efficiency and simultaneously expresses two heterotypes of HGF and dHGF (deleted variant HGF). Further the gene may be used for treating or preventing ischemic or liver diseases.

OTHER PUBLICATIONS

Seki, T., et al., "Isolation and Expression of cDNA for Different Forms of Hepatocyte Growth Factor from Human Leukocyte," *Biochem. Biophys. Res. Commun.* 172:321-327, Academic Press (1990).

Seki, T., et al., "Organization of the human hepatocyte growth factor-encoding gene," *Gene* 102:213-219, Elsevier/North-Holland (1991).

Shima, N., et al., "Hepatocyte Growth Factor and its Variant with a Deletion of Five Amino Acids are Distinguishable in their Biological Activity and Tertiary Structure," *Biochem. Biophys. Res. Commun.* 200:808-815, Academic Press (1994).

Warnecke C. et al., "Efficient transcription of the human angiotensin II type 2 receptor gene requires intronic sequence elements," *Biochemical journal*, 1999, 340 (1), pp. 17-24, Portland Press, Colchester, Great Britain.

Wishart et al., "A Single Mutation Converts a Novel Phosphotyrosine Binding into a Dual-Specificity Phosphatase," *Journal of Biological Chemistry*, 1995, 270 (45), pp. 26782-26785, American Society for Biochemistry and Molecular Biology, Bethesda, MD, USA.

Witkowski et al., "Conversion of a A-Ketoacyl Synthase to a Malonyl Decarboxylase by Replacement of the Active-Site Cysteine with Glutamine," *Biochemistry*, 1999, 38 (36), pp. 11643-11650, American Chemical Society, Washington, DC, USA.

European Search Report for European Application No. EP 03 74 4561, mailed Apr. 18, 2006, European Patent Office, Munich, Germany.

Office Action for Co-pending U.S. Appl. No. 10/944,277, mailed Jan. 9, 2008.

Office Action for Co-Pending U.S. Appl. No. 10/944,277, mailed Feb. 13, 2009.

Notice of Allowance and Fees Due for Co-Pending U.S. Appl. No. 10/944,277, mailed May 29, 2009.

Notice of Allowance and Fees Due for Co-Pending U.S. Appl. No. 10/944,277, mailed Oct. 23, 2009.

Office Action for Co-pending U.S. Appl. No. 11/957,170, mailed Jan. 28, 2010.

Esp@cenet Database, English language abstract of JP 11-246433 A, published Sep. 14, 1999 (listed as document FP5 on the accompanying form PTO/SB/08A).



FIG. 1

FIG. 2

HepG2 genomic DNA

PCR

- ① Primers SEQ ID No.3+ SEQ ID.No.4 → F2
- ② Primers SEQ ID No.3 + SEQ ID No.5 → F3
- ③ Primers SEQ ID No.6 + SEQ ID No.7 → F5
- ④ Primers SEQ ID No.8 + SEQ ID No.7 → F7
- ⑤ Primers SEQ ID No.9 + SEQ ID No.7 → F8
- ⑥ Primers SEQ ID No.10 + SEQ ID No.7→ F6




Inserting into pGEM-T-easy

HGF- F_s

pGEM-T-easy-HGF-F2
pGEM-T-easy-HGF-F3
pGEM-T-easy-HGF-F5
pGEM-T-easy-HGF-F7
pGEM-T-easy-HGF-F8
pGEM-T-easy-HGF-F6

FIG. 3







FIG. 4B


FIG. 5


FIG. 6


FIG. 7


FIG. 8




FIG. 9

FIG. 10





**HYBRID HEPATOCYTE GROWTH FACTOR
GENE HAVING HIGH EXPRESSION
EFFICIENCY OF TWO HETERO TYPES OF
HEPATOCYTE GROWTH FACTOR**

This application is a continuation of U.S. application Ser. No. 10/944,277, filed Sep. 20, 2004, which is a continuation of International Application No. PCT/KR03/00548, filed Mar. 20, 2003, which claims priority benefit to Korean Appl. No. 10-2002-0015074, filed Mar. 20, 2002, each of which are herein incorporated by reference in their entirety.

**REFERENCE TO A SEQUENCE LISTING
SUBMITTED ELECTRONICALLY**

The content of the electronically submitted sequence listing ("sequencelisting.ascii.txt", 29,879 bytes, created on Dec. 30, 2009) filed with the application is incorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to a highly efficient hybrid Hepatocyte Growth Factor (HGF) gene which simultaneously expresses two heterotypes of HGF.

2. Related Art

The present invention relates to a hybrid HGF gene prepared by inserting an inherent or foreign intron between exons 4 and 5 in HGF cDNA, which has higher expression efficiency than HGF cDNA and simultaneously expresses two heterotypes of HGF and dHGF (deleted variant HGF).

HGF is a heparin binding glycoprotein called a scatter factor. A gene encoding HGF is located at chromosome 721.1 and comprises 18 exons and 17 introns, having the nucleotide sequence of SEQ ID NO: 1 (Seki T., et al., *Gene* 102:213-219 (1991)). A transcript of about 6 kb is transcribed from the HGF gene, and then, a polypeptide HGF precursor consisting of 728 amino acids is synthesized therefrom. Simultaneously, a polypeptide of dHGF precursor consisting of 723 amino acids is also synthesized by an alternative splicing of the HGF gene. The biologically inactive precursors may be converted into active forms of disulfide-linked heterodimer by protease in serum. In the heterodimers, the alpha chain having a high molecular weight forms four kringle domains and an N-terminal hairpin loop like a preactivated peptide region of plasminogen. The kringle domains of a triple disulfide-bonded loop structure consisting of about 80 amino acids may play an important role in protein-protein interaction. The low molecular weight beta chain forms an inactive serine protease-like domain. dHGF consisting 723 amino acids is a polypeptide with deletion of five amino acids in the 1st kringle domain of the alpha chain, i.e., F, L, P, S and S.

It has been recently reported that both of HGF and dHGF have several biological functions, e.g., promoting the growth and morphogenesis of epithelial cell, melanocyte and endothelial cell. However, they are different in terms of immunological or biological properties.

For example, HGF shows about 20-fold, 10-fold and 2-fold higher activities than dHGF in promoting DNA synthesis in human umbilical cord venous endothelial cell, arterial smooth muscle cell and NSF-60 (murine myeloblast cell), respectively. dHGF shows about 3-fold and 2-fold higher activities than HGF in promoting DNA synthesis of LLC-PK1 (pig kidney epithelial cell), and OK (American opossum kidney epithelial cell) and mouse interstitial cell, respectively. HGF has a 70-fold higher solubility in PBS than dHGF.

Several anti-dHGF monoclonal antibodies recognize only dHGF, but not HGF or a reduced form of dHGF, which implies structures of HGF and dHGF are different. Accordingly, the simultaneous synthesis of HGF and dHGF in vivo suggests that they biologically interact with each other (Shima, N. et al., *Biochemical and Biophysical Research Communications* 200:808-815 (1994)).

HGF secreted from mesoderm-derived cells has various biological functions, e.g., 1) inducing epithelial cells into a tubular structure; 2) stimulating vascularization from endothelial cells in vitro and in vivo; 3) regeneration of liver and kidney, owing to its anti-apoptosis activity; 4) organogenesis of kidney, ovary and testis; 5) controlling osteogenesis; 6) stimulating the growth and differentiation of erythroid hematopoietic precursor cells; and 7) axon sprouting of neurons (Stella, M. C. and Comoglio, P. M., *The International Journal of Biochemistry & Cell Biology* 31:1357-1362 (1999)). Based on these various functions, HGF or a gene encoding HGF may be developed as a therapeutic agent for treating ischemic or liver diseases. Actually, in vivo, the HGF may exist as either HGF or dHGF, and therefore, the coexpression of HGF and dHGF is important for maximizing the therapeutic effect. Accordingly, the present inventors have endeavored to develop a hybrid HGF gene which can simultaneously express HGF and dHGF with a high efficiency for gene therapy.

SUMMARY OF THE INVENTION

Accordingly, it is a primary object of the present invention to provide a hybrid HGF gene which simultaneously expresses two heterotypes of HGF.

In accordance with one aspect of the present invention, there is provided the hybrid HGF gene having an inherent or foreign intron inserted between exons 4 and 5 of HGF cDNA.

It is another object of the present invention to provide a recombinant vector comprising the hybrid HGF gene and a microorganism transformed with the above vector.

It is still further object of the present invention to provide a pharmaceutical composition for treating or preventing ischemic or liver diseases, which comprises the HGF gene.

BRIEF DESCRIPTION OF THE DRAWINGS

The above and other objects and features of the present invention will become apparent from the following description of the invention, when taken in conjunction with the accompanying drawings which respectively show:

FIG. 1: a schematic diagram of HGF-X prototype illustrating the positions of the gene fragments,

FIG. 2: a process for cloning gene fragments from HepG2 genomic DNA,

FIG. 3: a process for cloning gene fragments from human placenta cDNA,

FIGS. 4A and 4B: processes for preparing expression vectors pCK-HGF-X,

FIG. 5: a process for preparing expression vectors pCK-HGF and pCK-dHGF,

FIG. 6: a process for preparing expression vectors pCP-HGF-X family,

FIG. 7: a process for preparing expression vectors pCP-HGF and pCP-dHGF,

FIG. 8: gene expression levels of pCP-cHGF, pCP-dHGF and pCP-HGF-X.

FIG. 9: gene expression patterns of pCP-cHGF, pCP-dHGF and pCP-HGF-X observed by electrophoresis on 12% polyacrylamide gel,

FIG. 10: gene expression levels of pCP-cHGF, pCP-dHGF and pCP-HGF-X7, in vivo,

FIG. 11: cerebral angiogenesis of two groups of rabbits which were subject to administrating pCP and pCP-HGF-X7, respectively,

DETAILED DESCRIPTION OF THE INVENTION

The hybrid Hepatocyte Growth Factor (HGF) gene of the present invention comprises cDNA corresponding to the exons 1 to 18, and an inherent or foreign intron inserted between exons 4 and 5 of the cDNA. The intron comprises a fragment of the inherent intro or a recombinant sequence.

An embodiment of the hybrid HGF gene of the present invention comprising the inherent intron is 7113 bp long and has the nucleotide sequence of SEQ ID NO: 2. The hybrid HGF gene simultaneously expresses both HGF and dHGF, and has higher expression efficiency than HGF cDNA.

Codon degeneracy enables the hybrid HGF gene of the present invention to be modified or changed in the coding and/or non-coding region without altering the amino acid sequence of the protein and the expression of the gene. Accordingly, polynucleotides which is substantially identical to the hybrid HGF gene of SEQ ID NO:2, and the fragments thereof fall within the scope of the invention. "Substantially identical" means that the sequence homology is not less than 80%, preferably not less than 90%, and more preferably not less than 95%.

A hybrid HGF gene may comprise a fragment of inherent intron optionally having a small recombinant sequence inserted thereinto between exons 4 and 5 of HGF cDNA. Herein, such a hybrid HGF gene comprising a fragment of inherent intron designates "HGF-X". HGFX-6, HGF-X7 and HGF-X8 having the nucleotide sequence of SEQ ID Nos: 19 to 21, respectively, are preferred.

The hybrid HGF gene of the present invention is synthesized and inserted into an expression vector, according to the known genetic engineering methods. Then, the vector can be introduced into an appropriate host cells such as *E. coli* and yeast. For example, *Escherichia coli* Top10F' may be transfected with HGF-X7 gene of the present invention. *Escherichia coli* Top10F' pCK-HGFX7 and *Escherichia coli* Top10F' pCP-HGFX7 then obtained were deposited as the accession numbers KCCM-10361 and KCCM-10362, respectively, on Mar. 12, 2002.

By using the transformed cells, the gene of the present invention and the protein encoded thereby may be produced on a large scale.

The vector of the present invention may selectively comprise sequence(s) for regulating gene expression such as promoter or terminator, self-replication sequence and secretory signal, depending on host cells.

Further, the present invention comprises a pharmaceutical composition for treating or preventing ischemic and liver diseases, which comprises the hybrid HGF gene or the vector comprising the gene as an active ingredient. Preferably, the composition is formulated for injection.

The composition of the present invention may further comprise pharmaceutically acceptable carriers. Any of the conventional procedures in the pharmaceutical field may be used to prepare oral formulations such as tablets, capsules, pills, granules, suspensions and solutions; injection formulations such as solutions, suspensions, or dried powders that may be

mixed with distilled water before injection; locally-applicable formulations such as ointments, creams and lotions; and other formulations.

Carriers generally used in the pharmaceutical field may be employed in the composition of the present invention. For example, orally-administered formulations may include binders, emulsifiers, disintegrating agents, excipients, solubilizing agents, dispersing agents, stabilizing agents, suspending agents, coloring agents or spicery. Injection formulations may comprise preservatives, unagonizing agents, solubilizing agents or stabilizing agents. Preparation for local administration may contain bases, excipients, lubricants or preservatives. Any of the suitable formulations known in the art (Remington's Pharmaceutical Science [the new edition], Mack Publishing Company, Eaton Pa.) may be used in the present invention.

The inventive composition can be clinically administered as various oral and parenteral formulations. A suitable formulation may be prepared using such excipients as additives, enhancers, binders, wetting agents, disintegrating agents and surfactants, or diluents. Solid formulations for oral administration include pills, tablets, dusting powder, granules and capsules. Those solid formulations may be prepared by mixing one or more excipients, e.g. starch, calcium carbonate, sucrose, lactose and gelatin with dibenzylbutyryl lactone lignan derivatives. Also, lubricants such as magnesium stearate and talc may be included in the present formulation. Liquid formulations for oral administration include suspension, solution, emulsion and syrup. Those formulations may contain wetting agents, sweeteners, aromatics and preservatives, in addition to general simple diluents such as water and liquid paraffin. Formulations for parenteral administration include sterilized aqueous solution, suspension, emulsion, freeze-dried alternative treatment and suppositories. Water-insoluble excipients and suspending agents comprise vegetable fats such as propylene glycol, polyethylene glycol and olive oil, and injectable esters such as ethyl oleate. Witepsol®, Macrogol®, Tween® 61, cacao fats, laurin fats and glycerogelatins may be used as bases of suppositories.

The inventive composition may be administered orally or via parenteral routes such as intravenous, intramuscular, subcutaneous, intraabdominal, sternal and arterial injection or infusion, or topically through rectal, intranasal, inhalational or intraocular administration.

It should be understood that the typical daily dose of composition of the present invention ought to be determined in light of various relevant factors including the conditions to be treated, the chosen route of administration, the age, sex and body weight of the individual patient, and the severity of the patient's symptom, and can be administrated in a single dose or in divided dose. Therefore, the daily dose should not be construed as a limitation to the scope of the invention in any way.

The following Examples are given for the purpose of illustration only, and are not intended to limit the scope of the invention.

EXAMPLE 1

Preparation of Hybrid Gene Constructs Encoding Human HGF

(1) Cloning of HGF Gene Fragments Obtained from Genomic DNA

Human HepG2 cells (ATCC Accession NO: HB-8065) were suspended in TES buffer (10 mM Tris-HCl; 1 mM

EDTA; 0.7% SDS) and treated with 400 µg/Ml of proteinase K at 50° C. for 1 hour. Subsequently, genomic DNA was extracted from the cell suspension by phenol/chloroform extraction and ethanol precipitation according to the conventional method in the art.

In the PCR amplification, the extracted genomic DNA was employed as a template DNA. As primer pairs, the synthetic nucleotides of SEQ ID NOs: 3 and 4 were employed to obtain DNA fragments containing: HGF gene fragment 2 (HGF-F2), SEQ ID NOs: 3 and 5; HGF-F3, SEQ ID NOs: 6 and 7; HGF-F5, SEQ ID NOs: 8 and 7; HGF-F7, SEQ ID NOs: 9 and 7; HGF-F8, SEQ ID NOs: 10 and 7; HGF-F6, respectively (FIG. 1). The PCR amplification mixture was prepared by mixing 1 µl of template DNA, 1 µl each of primer (10 pmol/µl), 10 µl of dNTP (10 mM), 3.5 unit of Expand High Fidelity enzyme (Gibco BRL, USA) and 10 µl of enzyme buffer solution and adjusted to a final volume of 100 µl with distilled water. 30 cycles of the PCR amplification was carried out, each cycle consisting of 1 min at 94° C., 1 min at 55° C. and 30 sec at 72° C. The primers used herein and the amplified gene fragments obtained therefrom are shown in Table 1.

TABLE 1

5' primer	3' primer	Amplified fragment
gHGF3 (SEQ ID NO: 3)	gHGF4 (SEQ ID NO: 4)	HGF gene fragment 2 (HGF-F2)
gHGF3 (SEQ ID NO: 3)	gHGF10 (SEQ ID NO: 5)	HGF gene fragment 3 (HGF-F3)
gHGF5 (SEQ ID NO: 6)	gHGF7 (SEQ ID NO: 7)	HGF gene fragment 5 (HGF-F5)
gHGF12 (SEQ ID NO: 8)	gHGF7 (SEQ ID NO: 7)	HGF gene fragment 7 (HGF-F7)
gHGF13 (SEQ ID NO: 9)	gHGF7 (SEQ ID NO: 7)	HGF gene fragment 8 (HGF-F8)
gHGF6 (SEQ ID NO: 10)	gHGF7 (SEQ ID NO: 7)	HGF gene fragment 6 (HGF-F6)

The amplified HGF-F2 comprised the sequence ranging from 392 to 2247 of human HGF cDNA prototype (HGF-X1; composed of exons 1 to 4-intron 4-exons 5 to 18) of SEQ ID NO: 2; HGF-F3, the sequence ranging from 392 to 727; HGF-5, the sequence ranging from 2229 to 5471; HGF-F6, the sequence ranging from 5117 to 5471; HGF-F7, the sequence ranging from 3168 to 5471; and HGF-F8, the sequence ranging from 4168 to 5471.

The amplified HGF gene fragments were each inserted into the multiple cloning site of pGEM-T easy vector (Promega, WI, USA) to obtain pGEM-T easy-HGF-F2, pGEM-T easy-HGF-F3, pGEM-T easy-HGF-F5, pGEM-T easy-HGF-F6, pGEM-T easy-HGF-F7 and pGEM-T easy-HGF-F8, respectively (FIG. 2). The nucleotide sequences of the amplified HGF gene fragments were confirmed by a sequence analysis.

(2) Cloning of HGF Gene Fragments Obtained from cDNA

In the PCR amplification, human placenta cDNA (Clontech, CA, USA) was employed as a template DNA under the same condition as described in Example 1. As primer pairs, the synthetic oligonucleotides of SEQ ID NOs: 11 and 12, and SEQ ID NOs: 13 and 14 were employed to obtain DNA fragments containing HGF-F1 and HGF-F4, respectively. Further, DNA fragments containing cDNAs of HGF gene (cHGF) and deleted HGF gene (dHGF) were amplified by PCR using synthetic oligonucleotides of SEQ ID NOs: 15 and 16 as a primer pair, respectively. dHGF is a HGF gene with deletion of 5 base sequences.

The primers used herein and the amplified gene fragments obtained therefrom are shown in Table 2.

TABLE 2

5' primer	3' primer	Amplified fragment
gHGF1 (SEQ ID NO: 11)	gHGF2 (SEQ ID NO: 12)	HGF gene fragment 1 (HGF-F1)
gHGF8 (SEQ ID NO: 13)	gHGF9 (SEQ ID NO: 14)	HGF gene fragment 4 (HGF-F4)
cHGF5 (SEQ ID NO: 15)	cHGF3 (SEQ ID NO: 16)	HGF gene cDNA (cHGF) dHGF gene cDNA (dHGF)

The amplified HGF-F1 and HGF-F4 comprised the nucleotide sequences ranging from 1 to 402 and from 6533 to 7113 of SEQ ID NO: 2 of human HGF cDNA prototype, respectively. HGF gene cDNA comprised the nucleotide sequence ranging from 1 to 2184 of SEQ ID NO: 1 of human HGF gene, and dHGF gene cDNA has the same sequence as HGF gene cDNA except for the deletion of the sequence ranging from 483 to 495.

The amplified fragments of HGF gene were each inserted into the multiple cloning site of pGEM-T easy vector (Promega, WI, USA) to obtain pGEM-T easy-HGF-F1, pGEM-T easy-HGF-F4, pGEM-T easy-cHGF and pGEM-T easy-dHGF, respectively (FIG. 3). The nucleotide sequences of the human HGF gene fragments, HGF gene cDNA and dHGF gene cDNA were confirmed by sequence analyses.

(3) Preparation of Hybrid HGF Gene Constructs

Hybrid HGF gene constructs of genomic DNA and cDNA were prepared by combining the fragments of HGF gene cloned in steps (1) and (2) as follows (FIGS. 4A and 4B).

Plasmid pGEM-T-easy-HGF-F1 was treated with HindIII/BamHI to obtain HGF-F1. Plasmid pCK (see PCT International Publication NO: WO/0040737) was treated with HindIII/BamHI, and HGF-F1 was inserted thereinto to obtain pCK-F1. And then, plasmids pGEM-T-easy-HGF-F2 and pGEM-T-easy-HGF-F3 were treated with MluI/BamHI to obtain HGF-F2 and HGF-F3, respectively. pCK-1 was treated with MluI/BamHI, and then HGF-F2 and HGF-F3 were inserted thereinto to obtain pCK-F12M and pCKF13M. The MluI restriction site of vectors pCK-F12M and pCK-F13M was substituted with an Hgal restriction site by employing a site-directed mutagenesis kit (Stratagene, CA., USA) to obtain pCK-F12 and pCK-F13, respectively.

Further, plasmid pGEM-T-easy-HGF-F4 was treated with BamHI/XbaI to obtain HGF-F4. pCK-F12 and pCK-F13 were treated with BamHI/XbaI, and HGF-F4 was inserted thereinto to obtain pCK-F124 and pCK-F134, respectively. And then, plasmids pGEM-T-easy-HGF-F5, pGEM-T-easy-HGF-F6, pGEM-T-easy-HGF-F7 and pGEM-T-easy-HGF-F8 were treated with BamHI/XbaI to obtain HGF-F5, HGF-F6, HGF-F7 and HGF-F8, respectively. pCK-F124 and pCK-F134 were treated with BamHI/XbaI, and then HGF-F5, HGF-F6, HGF-F7 and HGF-F8 were inserted thereinto to obtain pCK-F1254 and pCK-F1264, pCK-F1274, pCK-F1284, pCK-F1354, pCK-F1364, pCK-F1374 and pCK-F1384, respectively.

And then, pGEM-T easy-cHGF was treated with XbaI to obtain cDNA fragment of HGF gene (HGF-XbaI) of about 1100 bp. Then, HGF-XbaI was inserted into pCK-F1254, pCK-F1264, pCK-F1274, pCK-F1284, pCK-F1354, pCK-F1364, pCK-F1374 and pCK-F1384 to obtain pCK-HGF-X1, pCK-HGF-X2, pCK-HGF-X3, pCK-HGF-X4, pCK-HGF-X5, pCK-HGF-X6, pCK-HGF-X7 and pCK-HGF-X8, respectively. On the other hand, pGEM-T easy-cHGF and pGEM-T easy-dHGF were treated with BamHI to obtain HGF gene cDNA and dHGF gene cDNA. Then, HGF gene

cDNA and dHGF gene cDNA were inserted into the BamHI restriction site of pCK to obtain pCK-cHGF and pCK-dHGF, respectively (FIG. 5).

(4) Preparation of an Expression Vector Containing a Hybrid HGF Gene Construct

Plasmid pcDNA3.1 (Invitrogen, USA) was digested with NdeI, treated with the Klenow fragment to build blunt ends, and then digested with NheI to obtain a DNA fragment containing human cytomegalovirus promoter. Plasmids pCK-HGF-X1, pCK-HGF-X2, pCK-HGF-X3, pCK-HGF-X4, pCK-HGF-X5, pCK-HGF-X6, pCK-HGF-X7 and pCK-HGF-X8 were digested with SnaBI, treated with the Klenow fragment to make blunt ends and digested with NheI, and then the above DNA fragment containing human cytomegalovirus promoter was inserted thereinto to obtain pCP-HGF-X1, pCP-HGF-X2, pCP-HGF-X3, pCP-HGF-X4, pCP-HGF-X5, pCP-HGF-X6, pCP-HGF-X7 and pCP-HGF-X8, respectively (FIG. 6).

Plasmid pcDNA3.1 (Invitrogen, USA) was digested with NheI, treated with the Klenow fragment to make blunt ends and digested with NdeI to obtain the DNA fragment containing human cytomegalovirus promoter. pCK-cHGF and pCK-dHGF were digested with MluI, treated with the Klenow fragment to make blunt ends and digested with NdeI, and then the above DNA fragment containing human cytomegalovirus promoter was inserted thereinto to obtain pCP-cHGF and pCP-dHGF, respectively (FIG. 7).

EXAMPLE 2

Examination of the Expression Efficiency of Hybrid HGF Gene Construct and the Coexpression of HGF/dHGF

Studies was conducted to examine whether the hybrid HGF gene constructs (HGF-X1 to HGF-X8) obtained in Example 1 can simultaneously express HGF and dHGF and whether there is any difference in the gene expression level between hybrid HGF gene constructs and HGF cDNA.

(1) Gene Expression Efficiency

First, 5 µg of pCP-HGF-X2, pCP-HGF-X3, pCP-HGF-X6, pCP-HGF-X7 and pCP-HGF-X8 were transfected into 5×10^6 cells of 293 cell (ATCC CRL 1573) together with 0.5 µg of DONAI-LacZ (TAKARA SHUZO, Japan) DNA using FuGENE6 (Gibco BRL, MD, USA), according to the manufacturer's instructions. At this time, 5 µg each of pCP-cHGF and pCP-dHGF were used as controls, and DONAI-LacZ DNA was used to calibrate the infection efficiency. 3 hours after transfection, cells were re-fed with a fresh medium and further cultured for 48 hours. The culture solution thus obtained was divided into two parts. One part of the 293 cell culture solution was subjected to RNA extraction, and the other, to measurement of LacZ activity. The LacZ activity was measured using an activity measuring kit (Stratagene, CA, USA) according to the manufacturer's instructions.

In order to compare the gene expression levels, the amount of HGF in the cell culture was measured by an enzyme-linked immunosorbent assay kit (ELISA, R&D System, MN, USA). After calibrating the infection efficiency by the measured LacZ activity, the expression level of HGF-X gene was found to be from 20 to 150-fold higher than those of HGF cDNA and dHGF cDNA (FIG. 8). HGF-X7, in particular, showed the highest gene expression level.

(2) Coexpression of HGF and dHGF

In order to examine coexpression of HGF and dHGF from hybrid HGF gene constructs, total cellular RNAs were extracted from the transfected 293 cells using the Trizol method (Trizol; Gibco BRL, USA) and subjected to RT-PCR to obtain cDNA. Then, using cDNA as a template DNA, PCR amplification was carried out using synthetic oligonucleotides of SEQ ID NOs: 17 and 18 as a primer pair. The PCR amplification mixture was prepared by mixing 1 µl of the template DNA, 1 µl each of the primer (10 pmol/µl), 10 µl of dNTP (10 mM), 3.5 unit of Taq polymerase (TAKARA SHUZO, Japan) and 10 µl of enzyme buffer solution and adjusted to a final volume of 100 µl with distilled water. 30 cycles of PCR amplification was conducted, each cycle consisting of 1 min at 94°C., 1 min at 55°C., and 90 sec at 72°C.

The amplified PCR products corresponded to the boundary region between exons 4 and 5 of HGF gene; HGF gene cDNA of 142 bp and dHGF gene cDNA of 127 bp, respectively. With no splicing, the PCR product of at least 1 kb in length was amplified; and if alternative splicing occurred, HGF gene cDNA of 142 bp and dHGF gene cDNA of 127 bp were simultaneously synthesized and amplified. The amplified PCR products were distinguished by electrophoresis on a 12% polyacrylamide gel.

As shown in FIG. 9, while the bands of 142 bp and 127 bp were detected in the lanes loading HGF gene cDNA and dHGF gene cDNA, respectively, both bands of 142 bp and 127 bp were detected in the lanes loading HGF-X. The above results suggest that HGF and dHGF are simultaneously expressed from hybrid HGF-X gene constructs of the present invention.

EXAMPLE 3

Comparison of Expression Levels of HGF-X7, HGF Gene cDNA and dHGF Gene cDNA (In Vivo)

100 µg each of pCP-HGF-X7, pCP-cHGF and pCP-dHGF were injected into the exterior tibial muscle of the hind limb 40 of mice with an insulin syringe. After 5 days, the mice were sacrificed and the muscles around the injection spot were removed and smashed in a protein extraction buffer (25 mM Tris-HCl (pH 7.4), 50 mM NaCl, 0.5% Na-deoxycholate, 2% NP-40, 0.2% SDS) to separate total proteins. The amount of 45 the total proteins was measured with a DC protein analysis kit (Bio-Rad Laboratories, CA, USA) and the amount of expressed HGF was determined with an ELISA kit (R&D System) according to the manufacturer's instruction.

As can be seen from the result shown in FIG. 10, the 50 amount of HGF expressed from HGF-X7 is 250-fold higher than that from HGF gene cDNA or dHGF gene cDNA.

Together with the result of the experiment of Example 2 (in vivo), this result demonstrates that the expression efficiency of HGF-X gene is much superior to those of HGF gene cDNA 55 or dHGF gene cDNA.

EXAMPLE 4

Gene Therapy Employing HGF-X7 in a Rabbit Ischemic Hind Limb Model

In order to examine whether HGF-X7 gene is effective in the treatment of ischemic hind limb disease, gene therapy was carried out on a rabbit ischemic hind limb model as follows.

A rabbit ischemic hind limb model, which is a standard animal model for the ischemic limb disease, was prepared by the method described by Takeshita et al., *Journal of Clinical*

Investigation 93:662 (1994). At the day before operation (day 0), each of 30 white rabbits from New Zealand (male, from 3.8 to 4.2 kg) was intramuscularly injected with 5 mg/kg of xylazine and, then, anesthetized by an intramuscular injection of 50 mg/kg of ketamine. Subsequently, the left femoral region of the rabbit was incised and all branches of the femoral artery were separated and tied. The region from the proximal part to the branching point of the saphenous and popliteal arteries was incised to prepare the model. After the operation, 15 mg/kg/day of cefazolin was injected intramuscularly for 5 days and 0.3 mg/day of morphine, for 10 days. 10 days after the operation (day 10), angiography was carried out for the left hind limb where the ischemia was induced, and the degree of arteriogenesis was recorded as a basal level. The rabbits were randomly divided into two groups and injected at four sites in the femoral muscle with 500 µg of plasmid pCP-HGF-

X7 (experimental group) or 500 µg of plasmid pCP (control), respectively. 40 days after the operation (day 40), angiography was carried out again for the left hind limb and the degree of arteriogenesis at the arteriole level was determined and compared to that of day 10.

As can be seen from the result in FIG. 11, the degree of angiogenesis was significantly enhanced in the experimental group administered with pCP-HGF-X7 as compared with the pCP-administered control group.

This result demonstrates that HGF-X7 gene can be effectively used in the gene therapy of an ischemic disease.

While the invention has been described with respect to the above specific embodiments, it should be recognized that various modifications and changes may be made to the invention by those skilled in the art which also fall within the scope of the invention as defined by the appended claims.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 21

<210> SEQ ID NO 1
<211> LENGTH: 2187
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

atgtgggtga ccaaactcct gccagccctg ctgctgcagc atgtcctcct gcacatctcctc	60
ctgctccccca tcgccatccc ctatgcagag ggacaaagga aaagaagaaa tacaattcat	120
gaattcaaaa aatcagcaaa gactacccta atcaaaaatag atccagcact gaagataaaaa	180
accaaaaaaaaa tgaatactgc agaccaatgt gctaatacgat gtactaggaa taaaggactt	240
ccattcactt gcaaggcttt tgaaaaatgtt aaagcaagaa aacaatgcct ctgggtcccc	300
ttcaatagca tgtcaagtgg agtgaaaaaaa gaatttggcc atgaatttga cctctatgaa	360
aacaaagact acattagaaa ctgcatttcattt ggttaaaggac gcagctacaa gggAACAGTA	420
tctatcacta agagtggcat caaatgtcag ccctggagtt ccatgatacc acacgaacac	480
agctttttgc cttcgagcta tcggggtaaa gacctacagg aaaactactg tcgaaatcct	540
cgaggggaag aagggggacc ctgggttttca acaagcaatc cagaggtacg ctacgaagtc	600
tgtgacattt ctcagtgttc agaagttgaa tgcattgaccc gcaatggggaa gagttatcga	660
ggtctcatgg atcatacaga atcaggcaag atttgcacg gctggatca tcagacacca	720
cacccggcaca aattcttgcc tgaaagatata cccgacaagg gctttgatga taattattgc	780
cgcaatcccg atggccagcc gaggccatgg tgctatactc ttgaccctca cacccgctgg	840
gagtaactgtg caattaaaac atgcgctgac aatactatga atgacactga tgttcccttg	900
gaaacaactg aatgcattca aggtcaagga gaaggctaca ggggcactgt caataccatt	960
tggaaatggaa ttccatgtca gcggtggat tctcagtatc ctcacgagca tgacatgact	1020
cctgaaaatt tcaagtgcaa ggacctacga gaaaattact gccgaaatcc agatgggtct	1080
gaatcacccct ggtgtttac cactgatcca aacatccgag ttggctactg ctcccaaatt	1140
ccaaactgtg atatgtcaca tggacaagat tggtatcgtg ggaatggcaa aaatttatag	1200
ggcaacttat cccaaacaag atctggacta acatgttcaa tggggacaa gaacatggaa	1260
gacttacatc gtcatatctt ctgggaacca gatgcaagta agctgaatga gaattactgc	1320
cgaaatccag atgatgatgc tcatggaccc tgggtgtaca cgggaaatcc actcattcct	1380

- continued

tggattttt gccctatttc tcgttgtgaa ggtgatacca cacctacaat agtcaattta 1440
gaccatcccc taatatcttg tgccaaaacg aaacaattgc gagttgtaaa tgggattcca 1500
acacgaacaa acataggatg gatggtagt ttgagataca gaaataaaaca tatctgcgga 1560
ggatcattga taaaggagag ttgggttctt actgcacgac agtgtttccc ttctcgagac 1620
ttgaaagatt atgaagcttg gcttggattt catgatgtcc acggaagagg agatgagaaa 1680
tgcaaacagg ttctcaatgt ttcccagctg gtatatggcc ctgaaggatc agatctggtt 1740
ttaatgaagc ttgccaggcc tgctgtcctg gatgattttg ttagtacgat tgatttacct 1800
aattatggat gcacaattcc taaaaagacc agttgcagtg tttatggctg gggctacact 1860
ggattgatca actatgatgg cctattacga gtggcacatc tctatataat gggaaatgag 1920
aaatgcagcc agcatcatcg aggaaaggtg actctgaatg agtctgaaat atgtgctggg 1980
gctgaaaaaga ttggatcagg accatgtgag ggggattatg gtggcccaact tggttgtgag 2040
caacataaaaa tgagaatggt tcttgggtgtc attgttcctg gtcgtggatg tgccattcca 2100
aatcgtcctg gtattttgt ccgagtagca tattatgcaa aatggataca caaaattatt 2160
ttaacatata aggtaccaca gtcata 2187

<210> SEQ ID NO 2
<211> LENGTH: 7113
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 2

atgtgggtga ccaaactcct gccagccctg ctgctgcagc atgtcctcct gcacatctcc 60
ctgctccccca tcgccatccc ctatgcagag ggacaaaaggaa aaagaagaaa tacaattcat 120
gaattcaaaaa aatcagcaaa gactacccta atcaaaaatag atccagcact gaagataaaa 180
accaaaaaaag tgaatactgc agaccaatgt gctaataatgc gtactaggaa taaaggactt 240
ccattcactt gcaaggcttt tggttttgat aaagcaagaa aacaatgcct ctgggtcccc 300
ttcaatagca tgtcaagtgg agtgaaaaaa gaatttggcc atgaatttga cctctatgaa 360
aacaaagact acattagaaa ctgcatcatt ggtaaaggac gcagctacaa gggAACAGTA 420
tctatcacta agagtggcat caaatgtcag ccctggagtt ccatgataacc acacgaacac 480
aggtaagaac agtatgaaga aaagagatga agcctctgtc ttttttacat gttaacagtc 540
tcatattagt ccttcagaat aattctacaa tcctaaaata acttagccaa cttgctgaat 600
tgtattacgg caaggtttat atgaattcat gactgatatt tagcaaatga ttaattaata 660
tgttaataaaa atgttagccaa aacaatatct taccttaatg cctcaatttg tagatctcg 720
tatttgtgaa ataataacgt aaacttcgtt taaaaggatt cttcttcctg tctttgagaa 780
agtacggcac tgtgcagggg gagaggttga ttgtaaaaaa tcagaggtttag atgagaatct 840
tactgagggc tgagggttct ttaaccttgg tggatctcaa cattggttgc acattaaaat 900
cacctgctgc aagcccttga cgaatcttac tttagaagatg acaacacaga acaattaaaat 960
cagaatctct ggggagaata gggcaccagt attttttgag ctcccaccat gattccaaag 1020
tgcagccaaa tttgagaacc actgctaaaaa gctcaagctt cagattgacc agctttcca 1080
tctcacctat cgccctaaaga ccaaatttggaa taaatgtgtt cattacgaca gatgggtact 1140
attnaaagat gagtaaacac aatatactta ggctcgctcag actgagagtt ttaatcatca 1200
ctgagggaaaa acatagatat ctaatactga ctggagtatt agtcaaggct tatttcacac 1260
acaattttat cagaaaccaa agtagttaa aacagcttc cccttattag taatgcattg 1320

-continued

gagggtttac tttaccatgt accttgctga gcactgtacc ttgttaatct catttacttg	1380
taatgagaac cacacagcgg gtagtttat tggttctatt ttacacctat gacaaaactg	1440
aagcataaaa acacttagta agtttcagt gtcatgcaca actaggaagt gacatggcca	1500
gaatataagc ccagtcacca tcactctata acctgcgctt ttaacaactt cagggcatga	1560
cacatttggc cggtcagtag aaccatgct gtgatttgg tttgcagtgg tggtgatgac	1620
tgccttgttgc aatccacttt ttattctatt ccattttggg gacacaattc tgcaagatga	1680
ttcttcatta ggaaacagag atgagttatt gaccaacaca gaaagaaaaa gagtttgg	1740
ctccacactg ggattaaacc tatgatcttgc gcctaattaa cactagctag taagtgtcca	1800
agctgatcat ctctacaaca tttcaataac agaaaacaac aattttcaaa attagttact	1860
tacaattatg tagaaatgcc tctaaaacac agtattttcc ttatattaca aaaacaaaaa	1920
ttataattgg ttttgtcctc ttttgagagt ttgcattgg tttactccctg catagtgaag	1980
aaaacatttt atttaagtag atggatctaa gttttcatg aacaaaggaa tgacatttga	2040
aatacaatcct accctagtc aggagaatgc attagattaa ccttagtagag gtcttatttc	2100
accctgagtt ttctatgatc gtgattctct gctggaggag taattgtgaa atagatctct	2160
ctggaaactg gcttcctagt ccaatcagct cttttaccaa tgaacacttc cttgtgatata	2220
agatgtttat ggccgagagg atccagtata ttaataaaat cccttttgtt attcaatgag	2280
ggaaacacat aattttcatc aattagcagc ttatttggaaat atctgcatga tggtttaca	2340
cttttaagtgtt ttgactaaag attaatttttca cagaaaatag aaaaagaaat atgtttctgt	2400
ctggaggaat gatttattgt tgaccctaa attgaaatat tttacttagt gcttaatggaa	2460
aagatgatga aagatgatga aattaatgtaa gaagcttaac tagaaaatca ggtgacactga	2520
tatctacatc tgtatccttc attggccacc cagcattcat taatgaatca gatgatggaa	2580
tagatcaagt ttccctaggaa cacagtgaat attaaaagaa aacaaaggaa gcctagcacc	2640
tagaagacct agtttatatt tcaaagtata ttggatgtaa acccaatttt aaacatttcc	2700
tcacttgc tctttaaagc cttgccaaca gcaaggacag agaaccaaaa atagtgtata	2760
tatgaataaa tgcttattac agaatctgtc gactggcaca tgctttgtgt gtaatgggtt	2820
ctcataaaaca cttgttgaat gaacacacat aagtgaaaga gcatggctag gcttcataccc	2880
ttggtcaaat atgggggtct aaagaaaagc aggggaaata cattgggaca ctaacaaaaa	2940
aaaacagtta atttaggtaa aagataaaat acaccacaga atgaagaaaa gagatgaccc	3000
agactgctct ttaacacctca tgccttagag aggttttga tatgaattgc attcagaatt	3060
gtggaaagga gccccatcttt tcttttcatt ttgattttat taactccaaat gggggattt	3120
tattcggtt ttggccatata ctactttga tttctacatt attctctttt cttttctacc	3180
tgtatttgc ctaataaattt gttgactttaat taattcacta cttcctcaca gcttttttt	3240
ggctttacaa atccactgga aaggtatatg ggtgtatcac tttgtgtatt tcgggtgtca	3300
tgtgttagagg ggacaaaaat cctctctcaa actataaata ttgagtattt gtgtattgaa	3360
catttgctat aactactagg tttcttaaat aatcttaata tataaaatga tatagaaaaa	3420
ggggaaattat agttcgtatt attcatctaa gtgaagagat taaaacccag ggagtaata	3480
aattgtctaa ggactaaggt tgtataactat ttaggtgata gatatggggc aaccgtatgg	3540
gttttatgt taacaaataa acttctcacc actctaccat atcaactttt ccataaaaaga	3600
gagctatagt attctttgct taaataaatt tgatttagtgc atgacttctt gaaaacatata	3660

-continued

aaagcaaaaag tcacatttga ttctatcaga aaagtggata agccatggcc caaacaaaag	3720
atgcattaaa atattctgga atgtggagc taaaagtaag aaaaatgact ttttaaaaaa	3780
gtttactgtt aggaattgtg aaattatgct gaatttttgt tgcattataa ttttgcag	3840
tcatacggtc tgacaacctg tcttatttct atttccccat atgaggaatg ctagtaagt	3900
atggatatta actattacta cttagatgca ttgaagttgc ataatatgga taatacttca	3960
ctggttccct gaaaatgttt agttagtaat aagtctctta cactattgt tttgtccat	4020
aatttatatt ttctgaagac ttaactctag aatacactca tgtcaaaatg aaagaatttc	4080
attgcaaaaat attgcttggt acatgacgca tacctgtatt tgttttgtgt cacaacatga	4140
aaaatgtgg tttattagaa gtttcattgg gtaggaaaca cattgaatg gtatttacta	4200
agatactaaa atccttggac ttcactctaa ttttagtgcc atttagaact caaggtctca	4260
gtaaaaagtag aaataaagcc tgttaacaaa acacaagctg aatattaaaa atgtaactgg	4320
attttcaaag aaatgtttac tggtattacc ttagatgta tattctttat tatgatctt	4380
tgtgtaaagt ctggcagaca aatgcaatat ctaattgtt agtccaatat cacaaggcgt	4440
acaaaagtat aaaaaagact tggcctttc taatgtgtt aaatacttta tgctggtaat	4500
aacactaaga gtagggcact agaaattta agtgaagata atgtgttgca gttactgcac	4560
tcaatggcctt actattataa accaaaactg ggatcaacta gctccagtca gtcaaaatga	4620
tcaaaattat tgaagagaat aagcaattct gttctttatt aggacacagt agatacagac	4680
tacaaaagtgg agtgtgctt ataagaggta gcatttggta agtgcattt actctattat	4740
cccttggagc ttctcaaaaat aaccatataa ggtgttaat gttaaagggtt atggttcacac	4800
tcagtgccaca ggttaagctaa taggtgaga gaagctaat tacttactgg ggtctcacag	4860
taagaaaagtg agctgaagtt tcagcccaga tttaactggaa ttctggcctc tttattcatg	4920
ttacttcatg aatctgtttc tcaattgtgc agaaaaaagg gggctattta taagaaaagc	4980
aataaaacaaa caagtaatga tctcaaataa gtaatgcaag aaatagttag atttcaaaaat	5040
cagttggcagc gatttctcag ttctgtccta agtggccttgc ctcaatcacc tgctatctt	5100
tagtggagct ttgaaattat gtttcagaca acttcgattc agttcttagaa tgtttgactc	5160
agcaaaattca caggctcatc tttctaattt gatggtaat atggaaattc agctaaatgg	5220
atgttaataa aattcaaacg ttttaaggac agatgaaaat gacagaattt taaggtaaaa	5280
tatatgaagg aatataagat aaaggatttt tctaccttca gcaaaaacat acccactaat	5340
tagtaaaattt aataggcaaa aaaaagttgc atgctttat actgtaatga ttatcatttt	5400
aaaactagct ttttgccttc gagctatcg ggttaagacc tacaggaaaa ctactgtcga	5460
aatcctcgag gggaaqaagg gggaccctgg tgtttcacaa gcaatccaga ggtacgctac	5520
gaagtctgtg acattcctca gtgttcagaa gttgaatgca tgacactgaa tggggagagt	5580
tatcgaggc tcatggatca tacagaatca ggcaagattt gtcagcgctg ggatcatcag	5640
acaccacacc ggcacaaaattt cttgcctgaa agatatccc acaaggcctt tgatgataat	5700
tattgccgca atcccgatgg ccagccgagg ccatggtgct atactcttga ccctcacacc	5760
cgctggagct actgtgcaat taaaacatgc gctgacaata ctatgaatga cactgtatgtt	5820
ccttggaaa caactgaatg catccaaggta caaggagaag gctacagggg cactgtcaat	5880
accatttgga atggaattcc atgtcagcgt tgggatttctc agtacccatca cgagcatgac	5940
atgactcctg aaaatccaa gtgcaaggac ctacgagaaa attactgccc aaatccagat	6000
gggtctgaat caccctgggtg ttttaccact gatccaaaca tccgagttgg ctactgctcc	6060

-continued

caaattccaa actgtgatat gtcacatgga caagattgtt atcgtggaa tggcaaaaat	6120
tatatggca acttatccc aacaagatct ggactaacat gttcaatgtg ggacaagaac	6180
atgaaagact tacatcgta tatcttctgg gaaccagatg caagtaagct gaatgagaat	6240
tactgccgaa atccagatga ttagtgcata ggaccctggt gctacacggg aaatccactc	6300
attcccttggg attattgccc tatttctcgt tgtgaagggtg ataccacacc tacaatagtc	6360
aatttagacc atccccataat atcttgcgc aaaacgaaac aattgcgagt tgtaaatggg	6420
attccaacac gaacaaacat aggatggatg gttagttga gatacagaaa taaacatatac	6480
tgcggaggat cattgataaaa ggagagttgg gttcttactg cacgacagtg tttcccttct	6540
cgagacttga aagattatga agcttggtt ggaattcatg atgtccacgg aagaggagat	6600
gagaaatgca aacaggttct caatgtttcc cagctggat atggccctga aggatcagat	6660
ctggttttaa tgaagcttgc caggcctgtc gtcctggatg attttgttag tacgattgt	6720
ttacctaatt atggatgcac aattcctgaa aagaccagtt gcagtgtta tggctgggc	6780
tacactggat ttagtcaacta ttagtgccta ttacgagttgg cacatctcta tataatggga	6840
aatgagaaat gcagccagca tcatacgaggg aaggtgactc tgaatgagtc tgaaatatgt	6900
gctggggctg aaaagattgg atcaggacca tggatggggg attatggtgg cccacttgg	6960
tgtgagcaac ataaaatgag aatgggtttt ggtgtcattt ttccctggcg tggatgtgcc	7020
attccaaatc gtcctggat ttttgtccga gtagcatatt atgaaaaatg gatacacaaa	7080
attattttaa catataaggt accacagtca tag	7113

<210> SEQ ID NO 3	
<211> LENGTH: 34	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: gHGF3 primer	
<400> SEQUENCE: 3	
gtaaaggacg cgtctacaag ggaacagtat ctat	34

<210> SEQ ID NO 4	
<211> LENGTH: 27	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: gHGF4 primer	
<400> SEQUENCE: 4	
actggatcct ctcggccata aacatct	27

<210> SEQ ID NO 5	
<211> LENGTH: 34	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: gHGF10 primer	
<400> SEQUENCE: 5	
gaagcttagc accatgtggg tgaccaaact cctg	34

<210> SEQ ID NO 6	
<211> LENGTH: 27	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	

-continued

<223> OTHER INFORMATION: gHGF5 primer

<400> SEQUENCE: 6

tggccgagag gatccagtat attaata

27

<210> SEQ ID NO 7

<211> LENGTH: 27

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: gHGF7 primer

<400> SEQUENCE: 7

cccctcgagg atttcgacag tagttt

27

<210> SEQ ID NO 8

<211> LENGTH: 28

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: gHGF12 primer

<400> SEQUENCE: 8

gggatccctt cctttctacc tgtatgg

28

<210> SEQ ID NO 9

<211> LENGTH: 25

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: gHGF13 primer

<400> SEQUENCE: 9

gggatcctgg gtaaaacacat ttgaa

25

<210> SEQ ID NO 10

<211> LENGTH: 28

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: gHGF6 primer

<400> SEQUENCE: 10

gggatcctta tgtttcagac aacttcga

28

<210> SEQ ID NO 11

<211> LENGTH: 34

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: gHGF1 primer

<400> SEQUENCE: 11

gaagcttgcc accatgtggg tgaccaaact cctg

34

<210> SEQ ID NO 12

<211> LENGTH: 34

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: gHGF2 primer

<400> SEQUENCE: 12

gggatccaga acgcgtcctt taccgatgt gcag

34

-continued

<210> SEQ ID NO 13
<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: gHGF8 primer
<400> SEQUENCE: 13

gggatccctt ctcgagactt gaaagattat gaagc

35

<210> SEQ ID NO 14
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: gHGF9 primer
<400> SEQUENCE: 14

gtcttagagcg gccgctatga ctgtggtacc tt

32

<210> SEQ ID NO 15
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: cHGF5 primer
<400> SEQUENCE: 15

ggatccacgc gtagcagcac catgtgggtg accaaa

36

<210> SEQ ID NO 16
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: cHGF3 primer
<400> SEQUENCE: 16

ggatcctcta gattacttca gctatgactg tggtac

36

<210> SEQ ID NO 17
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: GHGF5' primer
<400> SEQUENCE: 17

caaatgtcag ccctggagtt ccatga

26

<210> SEQ ID NO 18
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: GHGF3' primer
<400> SEQUENCE: 18

ctggattgct tgtgaaacag ggt

23

<210> SEQ ID NO 19
<211> LENGTH: 4679
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: HGF-X6 gene

-continued

<400> SEQUENCE: 19

atgtgggtga	ccaaactcct	gccagccctg	ctgctgcagc	atgtcctcct	gcacatccctc	60
ctgctcccc	tcgcccattccc	ctatgcagag	ggacaaaagga	aaagaagaaa	tacaattcat	120
gaattcaaaa	aatcagcaaa	gactacccta	atcaaaaatag	atccagcact	gaagataaaa	180
accaaaaaag	tgaataactgc	agaccaatgt	gctaatacgat	gtactaggaa	taaaggactt	240
ccattcactt	gcaaggcctt	tgttttgat	aaagcaagaa	aacaatgcct	ctggttcccc	300
ttcaatagca	tgtcaagtgg	agtgaaaaaaaa	gaatttggcc	atgaatttga	cctctatgaa	360
aacaaagact	acattagaaa	ctgcatcatc	ggtaaaggac	gcagctacaa	gggaacagta	420
tctatcacta	agagtggcat	caaatgtcag	ccctggagtt	ccatgataacc	acacgaacac	480
aggttaagaac	agtatgaaga	aaagagatga	agcctctgtc	tttttacat	gttaacagtc	540
tcatattagt	ccttcagaat	aattctacaa	tcctaaaata	acttagccaa	cttgctgaat	600
tgtattacgg	caaggtttat	atgaattcat	gactgatatt	tagcaaatga	ttaattaata	660
tgttaataaa	atgttagccaa	aacaatatct	taccttaatg	cctcaatttg	tagatctcg	720
tatttgtgga	tcccttcctt	tctacctgta	tttgcctaa	taaattgttg	acttattaat	780
tcaactactc	ctcacagctt	tttttggct	ttacaaatcc	actggaaagg	tatatgggtg	840
tatcactttg	tgtatttcgg	tgtgcattgt	tagagggac	aaaaatcctc	tctcaaacta	900
taaatattga	gtatttgtgt	attgaacatt	tgctataact	actaggtttc	ttaaataatc	960
ttaatatata	aatgatata	gaaaaaggga	aattatagtt	cgtattattc	atctaagtga	1020
agagattaaa	acccagggag	taaataaatt	gtctaaggac	taaggttgta	tactattnag	1080
gtgatagata	tggggcaacc	gtatgggtt	tatgattaac	aaataaactt	ctcaccactc	1140
taccatatac	actttccat	aaaagagagc	tatagtattc	tttgcttaaa	taaatttgat	1200
tagtgcattga	cttcttgaaa	acatataaag	caaaagtac	atttgattct	atcagaaaag	1260
ttagtaagcc	atggccaaa	caaaagatgc	ataaaaat	tctggaaatga	tggagctaaa	1320
agtaagaaaa	atgactttt	aaaaaagttt	actgttagga	attgtgaaat	tatgctgaat	1380
tttagttgca	ttataatttt	tgtcagtcat	acggctctgac	aacctgtctt	atttctattt	1440
ccccatata	ggaatgttag	ttaagtatgg	atattaacta	ttactactta	gatgcattga	1500
agttgcataa	tatggataat	acttcactgg	ttccctgaaa	atgttttagtt	agtaataagt	1560
ctcttacact	atttgtttt	tccaataatt	tatattttct	gaagacttaa	ctctagaata	1620
cactcatgtc	aaaatgaaag	aatttcattt	caaaatattt	cttggtacat	gacgcatacc	1680
tgtatttgtt	tttgtgtcaca	acatgaaaaa	tgtatggttt	ttagaagttt	cattgggtag	1740
gaaacacatt	tgaatggat	ttactaagat	actaaaatcc	ttggacttca	ctctaatttt	1800
agtgcattt	agaactcaag	gtctcagtaa	aagtagaaat	aaagcctgtt	aacaaaacac	1860
aagctgaata	ttaaaaaatgt	aactggattt	tcaaagaaat	gtttactgg	attacctgt	1920
gatgtatatt	ctttattatg	atctttgt	taaagtctgg	cagacaaatg	caatatctaa	1980
ttgtttagtc	caatatacaca	agcagtacaa	aagtataaaa	aagacttggc	ctttctaat	2040
gtgttaaaat	actttatgct	ggtaataaca	ctaagagtag	ggcactagaa	attttaagt	2100
aagataatgt	gttgcagtt	ctgcactcaa	tggcttacta	ttataaacca	aaactggat	2160
cactaagctc	cagtcagtc	aaatgatcaa	aattattgaa	gagaataagc	aattctgttc	2220
tttatttagga	cacagtagat	acagactaca	aagtggagtg	tgcttaataa	gaggttagcat	2280
ttgttaagt	tcaattactc	tattatccct	tggagcttct	caaataacc	atataaggt	2340

-continued

taagatgtta aaggttatgg ttacactcgag tgcacaggta agctaataagg ctgagagaag	2400
ctaaattact tactggggtc tcacagtaag aaagttagt gaagtttcag cccagattta	2460
actggattct gggctcttta ttcatgttac ttcatgaatc tgtttctcaa ttgtcagaa	2520
aaaagggggc tatttataag aaaagcaata aacaaacaag taatgatctc aaataagtaa	2580
tgcaagaaat agtgagattt caaaatcagt ggcagcgtt tctcagttct gtcctaagtg	2640
gccttgctca atcacctgct atcttttagt ggagcttga aattatgttt cagacaactt	2700
cgattcagtt ctagaatgtt tgactcagca aattcacagg ctcatcttc taacttgatg	2760
gtgaatatgg aaattcagct aaatggatgt taataaaatt caaacgtttt aaggacagat	2820
gaaaatgaca gaattttaag gtaaaatata tgaaggaata taagataaag gattttcta	2880
ccttcagcaa aaacataccc actaattagt aaaattaata ggcaaaaaaa agttgcattc	2940
tcttatactg taatgattat cattttaaa ctagctttt gccttcgagc tatcggttta	3000
aagacctaca ggaaaactac tgtcgaaatc ctcgagggga agaagggggga ccctgggtt	3060
tcacaagcaa tccagaggta cgctacgaag tctgtgacat tcctcagtgt tcagaagttg	3120
aatgcattgac ctgcaatggg gagagttatc gaggtctcat ggatcataca gaatcaggca	3180
agatttgtca ggcgtggat catcagacac cacaccggca caaattcttgc cctgaaagat	3240
atccccacaa gggctttgtat gataattatt gccgcaatcc cgatggccag ccgaggccat	3300
ggtgctatac tcttgaccct cacacccgtt gggagttactg tgcaattaaa acatgcgtt	3360
acaatactat gaatgacact gatgttcattt tggaaacaac tgaatgcattc caaggtcaag	3420
gagaaggcta caggggcaact gtcaatacca tttggatgg aattccatgt cagcgttggg	3480
attctcagta tcctcacgag catgacatga ctccctgaaaa tttcaagtgc aaggacctac	3540
gagaaaaatta ctgccaaat ccagatgggt ctgaatcacc ctgggtttt accactgatc	3600
caaacatccg agttggctac tgctccaaa ttccaaactg tgatatgtca catggacaag	3660
attgttatcg tggaaatggc aaaaattata tggcaactt atccaaaca agatctggac	3720
taacatgttc aatgtggac aagaacatgg aagacttaca tcgtcatatc ttctggaaac	3780
cagatgcaag taagctgaat gagaattact gccgaaatcc agatgtatgt gctcatggac	3840
cctggtgcta cacggaaat ccactcattt cttggattt ttgccttatt tctcggttg	3900
aagggtatac cacacccata atagtcaatt tagaccatcc cgtaataatct tggccaaaa	3960
cgaaacaatt gcgagttgtt aatgggattt caacacgaac aaacatagga tggatgggtt	4020
gtttgagata cagaataaaa catatctcgag gaggatcatt gataaggag agttgggtt	4080
ttactgcacg acagtgtttc ctttcgttgc acattgaaaga ttatgttgc tggcttggaa	4140
ttcatgtatgtt ccacggaaaga ggagatgaga aatgcaaaaca ggttctcaat gtttcccagc	4200
tggatgattt tggatgttgc attgattttc ctaattatgg atgcacaatt cctgaaaaga	4260
ccagttgcag tggatgttgc tggggctaca ctggatttgc caactatgtt ggccttattac	4320
gagttggcaca tctctatata atggaaatgt agaaatgcag ccagcatcat cgaggaaagg	4380
tgactctgaa tgagtctgaa atatgtgttgc gggctgaaaa gattggatca ggaccatgtt	4440
agggggattt tggatgttgc cttgtttgtt agcaacataa aatgagaatg gttcttgggtt	4500
tcattgttcc tggatgttgc tggatgttgc caaatcgatcc tggatgtttt gtcggatgtt	4560
catattatgc aaaatggata cacaaaattt ttttaacata taaggtacca cagtcata	4620
catattatgc aaaatggata cacaaaattt ttttaacata taaggtacca cagtcata	4679

-continued

```

<210> SEQ ID NO 20
<211> LENGTH: 3679
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: HGF-X7 gene

<400> SEQUENCE: 20

atgtgggtga ccaaactcct gccagccctg ctgctgcagc atgtcctcct gcatctcctc      60
ctgctccccca tcgccatccc ctatgcagag ggacaaagga aaagaagaaa tacaattcat      120
gaattcaaaa aatcagcaaa gactacccta atcaaaatag atccagcact gaagataaaa      180
accaaaaaaag tgaataactgc agaccaatgt gctaatacgat gtactaggaa taaaggactt      240
ccattcactt gcaaggcttt tggtttgtat aaagcaagaa aacaatgcct ctgggtcccc      300
ttcaatagca tgtcaagtgg agtgaaaaaaa gaatttggcc atgaatttga cctctatgaa      360
aacaaagact acattagaaaa ctgcacatc ggtaaaggac gcagctacaa gggAACAGTA      420
tctatcacta agagtggcat caaatgtcag ccctggagtt ccatgatacc acacgaacac      480
aggttaagaac agtatgaaga aaagagatga agcctctgtc tttttacat gttaacagtc      540
tcatattagt ctttcagaat aattctacaa tcctaaaata acttagccaa cttgctgaat      600
tgttattacgg caaggtttat atgaattcat gactgatatt tagcaaattga ttaattaata      660
tgttaataaa atgttagccaa aacaatatct taccttaatg cctcaatttg tagatctcg      720
tatttggta tcctggtag gaaacacatt tgaatggat ttactaagat actaaaatcc      780
ttggacttca ctctaatttt agtgcattt agaactcaag gtctcagtaa aagtagaaat      840
aaaggctgtt aacaaaacac aagctgaata taaaaatgt aactggattt tcaaagaaat      900
gtttactggt attacctgta gatgtatatt ctttattatg atctttgtg taaagtctgg      960
cagacaaatg caatatctaa ttgttgagtc caatatcaca agcagtcacaa aagtataaaa      1020
aagacttggc ctttctaat gtgttaaaaat actttatgct ggtataaca ctaagagtag      1080
ggcactagaa attttaagtg aagataatgt gttgcagttt ctgcactcaa tggcttacta      1140
ttataaacc aactggat cactaagctc cagtcagtc aaatgatcaa aattattgaa      1200
gagaataagc aattctgttc tttattatgg cacagtagat acagactaca aagtggagtg      1260
tgcttaataa gagtagcat ttgttaagtg tcaattactc tattatccct tggagcttct      1320
caaaataacc atataagggtg taagatgtt aaggttatgg ttacactcag tgcacaggtt      1380
agctaatagg ctgagagaag ctaaattact tactgggttc tcacagtaag aaagtggact      1440
gaagtttcag cccagattt actggattct gggcttttta ttcatgttac ttcatgaatc      1500
tgtttctcaa ttgtgcagaa aaaagggggc tatttataag aaaagcaata aacaaacaag      1560
taatgatctc aaataagtaa tgcaagaaat agtgagattt caaaatcgtt ggcagcgatt      1620
tctcagttct gtcctaagtgc gccttgctca atcacctgct atcttttagt ggagcttgc      1680
aattatgttt cagacaactt cgattcagtt cttagatgtt tgactcagca aattcacagg      1740
ctcatcttc taacttgatg gtgaatatgg aaattcagct aaatggatgt taataaaaatt      1800
caaacgtttt aaggacagat gaaaatgaca gaattttaag gtaaaatata tgaaggaata      1860
taagataaaag gatttttcta ctttcagcaa aaacatacc actaattagt aaaattaata      1920
ggcaaaaaaaaaa agttgcattgc tcttatactg taatgattat cattttaaaa ctagtttt      1980
gccttcgagc tatcggggta aagacctaca gggaaactac tgcggaaatc ctcgagggga      2040
agaaggggaa ccctgggttt tcacaagcaa tccagaggta cgctacgaag tctgtgacat      2100

```

-continued

tcctcagtgt tcagaagggtt aatgcgtac ctgcaatggg gagagttatc gaggtctcat	2160
ggatcataca gaatcaggca agatttgtca gcgctggat catcagacac cacaccggca	2220
caaattctt cctgaaagat atcccgacaa gggctttgtat gataattatt gccgaatcc	2280
cgtatggccag ccgaggccat ggtgtatac tcttgaccct cacacccgct gggagtaactg	2340
tgcaattaaa acatgcgtc acaatactat gaatgacact gatgttcctt tggaaacaac	2400
tgaatgcac tcaaggtaag gagaaggcta caggggcaact gtcaatacca ttggaaatgg	2460
aattccatgt cagcggtggg atttcagta tcctcacgag catgacatga ctccgtaaaa	2520
tttcaagtgc aaggacctac gagaaaaatta ctgcccata ccagatgggt ctgaatcacc	2580
ctgggtttt accactgatc caaacatccg agttggctac tgctccaaa ttccaaactg	2640
tgatatgtca catggacaag attgttatcg tggaaatggc aaaaattata tggcaactt	2700
atcccaaaca agatctggac taacatgttc aatgtgggac aagaacatgg aagacttaca	2760
tcgtcatatc ttctggaaac cagatgcaag taagctgaat gagaattact gccgaaatcc	2820
agatgatgat gctcatggac cctgggtgta cacgggaaat ccactcatc cttgggatta	2880
ttgccctatt tctcggtgt aaggtgatac cacacctaca atagtcatt tagaccatcc	2940
cgttaatatct tggccaaaaa cgaaacaatt gcgagttgta aatgggattc caacacgaac	3000
aaacatagga tggatggta gtttgagata cagaataaaa catatctcg gaggatcatt	3060
gataaaggag agttgggttc ttactgcacg acagtgttc cttctcgag acttggaaaga	3120
ttatgaagct tggcttgaa ttcatgatgt ccacggaga ggagatgaga aatgcaaaaca	3180
ggttctcaat gtttccagc tggtatatgg ccctgaagga tcagatctgg tttatgaa	3240
gcttgcagg cctgctgtcc tggatgatt tggatgtacg attgatttac ctaattatgg	3300
atgcacaatt cctgaaaaga ccagttgcag tggatgttgc tggggctaca ctggattgt	3360
caactatgat ggcctattac gagtggcaca tctctatata atggaaatg agaaatgcag	3420
ccagcatcat cgagggagg tgactctgaa tgagtctgaa atatgtgctg gggctgaaaa	3480
gattggatca ggaccatgtg agggggatta tggtggccca cttgtttgtg agcaacataa	3540
aatgagaatg gtttttggtg tcattgtcc tggtcgtgaa tgtgccattc caaatcgccc	3600
tggatattttt gtccgagtag catattatgc aaaatggata cacaaaatta ttttaacata	3660
taaggtacca cagtcatac	3679

<210> SEQ_ID NO 21
 <211> LENGTH: 2729
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: HGF-X8 gene

<400> SEQUENCE: 21

atgtgggtga ccaaactcct gccagccctg ctgctgcagc atgtcctcct gcatctcc	60
ctgctccccca tcgcccattccc ctatgcagag ggacaaagga aaagaagaaa tacaattcat	120
gaattcaaaa aatcagcaaa gactacccta atcaaaatag atccagcact gaagataaaa	180
accaaaaaag tgaataactgc agaccaatgt gctaatacgat gtactaggaa taaaggactt	240
ccattcactt gcaaggctt tggatgttgc aaagcaagaa aacaatgcct ctgggtcccc	300
ttcaatagca tgtcaagtgg agtggaaaaa gaatttggcc atgaatttga cctctatgaa	360
aacaaagact acattagaaa ctgcatac ggtaaaggac gcagctacaa gggAACAGTA	420

-continued

tctatcacta agagtggcat caaatgtcag ccctggagtt ccatgatacc acacgaacac	480
aggttaagaac agtatgaaga aaagagatga agcctctgtc tttttacat gttAACAGTC	540
tcatattagt ccttcagaat aattctacaa tcctaaaata acttagccaa cttgctgaat	600
tgttacgg caaggTTTAT atgaattcat gactgatatt tagcaaATGA ttaattaATA	660
tgttaataAA atgttagccaa aacaatatCT tacCTtaatG CCTCAATTG tagatCTCG	720
tatttGTGGA tccttatGTT tcagacaACT tcgattCAGT tctAGAATGT ttGACTCAGC	780
aaattcacAG gctcatCTT ctaacttgat ggtGAATATG gaaATTcAGC taaATGGATG	840
ttaataAAAT tcaaACGTT taaggacAGA tgAAAATGAC agaATTtAA ggtAAAATAT	900
atgaagGAAT ataagataAA ggATTTCT acCTTCAGCA AAAACATACC cactaATTAG	960
taAAATTAA aggcaAAAAA aagttGcatG ctcttataCT gtaatGATTA tcatttAA	1020
actAGCTTT TGCCTTCAGG CTATCGGGT AAAGACCTAC AGGAAAACtA CTGTCGAAT	1080
cctcgaggGG aagaaggGGG accctggTGT ttcacaAGCA ATCCAGAGGT acgctacGAA	1140
gtctgtGACA ttccTCAgTG ttcAGAAGTT gaATGCAtGA CCTGCAATGG ggAGAGTTAT	1200
cgaggTCTCA tggatcataC agaATCAGGC aagATTGTC agcGCTGGGA tcatcAGACA	1260
ccacaccGGC acaaATTCTT gcctgAAAGA tatcccGACA agggCTTGA tgataATTAT	1320
tgccGcaatC ccgatGGCCA gCcGAGGCCA tggTGTATA ctcttgacCC tcacaccGC	1380
tgggAGTACT gtGCAATTAA AACATGCGCT gacaataCTA tgaatGACAC tGATGTTcCT	1440
ttggAAACAA ctGAATGCA tcaAGGTCAA ggAGAAGGCT acAGGGGcAc tGtCAATACC	1500
atTTGGAAATG gaattccATG tcAGCGTTGG gattCTCAGT atcCTCACGA GcatGACATG	1560
actcCTGAAA atttcaAGTG caaggACCTA CGAGAAAATT actGCCGAAA tCCAGATGGT	1620
ctGAATCACC ctggTGTttt accACTGATC CAAACATCCG AGTGGCTAC TGCTCCCaaa	1680
ttccAAACTG tGATATGTCA catggACAAG attGTTATG tggGAATGGC aaaaATTATA	1740
tggGCAACTT atccccAAACA agatCTGGAC taACATGTTc AATGTGGAC aAGAACATGG	1800
aAGACTTACA tCGTCAATAC ttctGGGAAC cAGATGCAAG TAAGCTGAAT gagaATTACT	1860
gccGAAATCC agatGATGAT GCTCATGGAC CCTGGTGTCA cacGGAAAT CCACTCATC	1920
cttgggATTt ttGccCTAtt tctcgTTGTG aaggTgatac cacACCTACA atAGTCAATT	1980
tagaccatCC cgtAATATCT tGtGCCAAA CGAAACAAATT GCGAGTTGTA AATGGGATTc	2040
caacacGAAC aaACATAGGA tggatGGtTA gtttgAGATA cAGAAATAAA cataCTGCG	2100
gaggatCATT gataAAGGAG agttGGGTTc ttACTGcAcG acAGTGTtTC CCTTCTCGAG	2160
acttGAAAGA ttatGAAGCT tggCTTGGAA ttCATGATGT CCACGGAAAGA GGAGATGAGA	2220
aatGCAAACA ggttCTCAAT gtttCCAGC tggTATATGG CCCTGAAAGGA tCAGATCTGG	2280
ttttAATGAA gcttGCCAGG CCTGCTGTCC tggatGATTt tGTTAGTACG attGATTAC	2340
ctaattatGG atgcacaATT CCTGAAAAGA CCAGTTGcAG tGTTTATGGC tggGGCTACA	2400
ctggattGAT caactatGAT ggccttattAC gagTGGcACA tctcttatATA atGGAAATG	2460
agAAATGcAG ccAGCAtCAT CGAGGGAAAGG tgACTCTGAA tgAGTCTGAA ATATGTGCTG	2520
gggCTGAAAAG gattGGATCA ggACCATGTG AGGGGGATTa tggTGGCCCA CTTGTTGTG	2580
agcaACATAA aatGAGAATG gttttGGGTG tcattGTTCC tggTCGTGGA tGtGCCATC	2640
caaATCGTCC tggTATTTTt GTCGAGTAG CATATTATGC AAAATGGATA cacAAAATTA	2700
ttttAACATA taaggTAACCA cAGTCAtag	2729

What is claimed is:

1. A method for co-expressing two heterotypes of Hepatocyte Growth Factor (HGF) comprising transforming or transfecting to a cell a DNA construct comprising:
 - (a) a promoter,
 - (b) a first cDNA which has the same sequence as exons 1-4 of the human HGF gene wherein said exons 1-4 are arranged in sequential order without an intron therebetween, or degenerates thereof which do not alter the amino acid sequence encoded by said first cDNA,
 - (c) a polynucleotide that has the same sequence as intron 4 of the HGF gene or a functional fragment thereof, and
 - (d) a second cDNA which has the same sequence as exons 5-18 of the human HGF gene wherein said exons 5-18 are arranged in sequential order without an intron therebetween, or degenerates thereof which do not alter the amino acid sequence encoded by said second cDNA;

wherein (c) is located between (b) and (d); and the HGF construct simultaneously encodes two heterotypes of human HGF.
2. The method of claim 1, wherein said intron has the same sequence as a fragment of intron 4 of the HGF gene.
3. The method of claim 2, wherein the construct comprises a nucleotide sequence not less than 90% identical to SEQ ID NO: 19.
4. The method of claim 3, wherein the construct comprises a nucleotide sequence not less than 95% identical to SEQ ID NO: 19.
5. The method of claim 4, wherein the construct comprises the sequence of SEQ ID NO: 19.
6. The method of claim 2, wherein the construct comprises a nucleotide sequence not less than 90% identical to SEQ ID NO: 20.
7. The method of claim 6, wherein the construct comprises a nucleotide sequence not less than 95% identical to SEQ ID NO: 20.

8. The method of claim 7, wherein the construct comprises the sequence of SEQ ID NO: 20.
9. The method of claim 2, wherein the construct comprises a nucleotide sequence not less than 90% identical to SEQ ID NO: 21.
10. The method of claim 9, wherein the construct comprises a nucleotide sequence not less than 95% identical to SEQ ID NO: 21.
11. The method of claim 10, wherein the construct comprises the sequence of SEQ ID NO: 21.
12. The method of claim 1, wherein the one intron has the same sequence as the full intron 4 of the HGF gene.
13. The method of claim 1, wherein the construct comprises a nucleotide sequence not less than 90% identical to SEQ ID NO: 2.
14. The method of claim 13, wherein the construct comprises a nucleotide sequence not less than 95% identical to SEQ ID NO: 2.
15. The method of claim 14, wherein the construct comprises the sequence of SEQ ID NO: 2.
16. The method of claim 1, wherein the construct further comprises a terminator sequence, a self-replication sequence, or a secretory signal.
17. The method of claim 1, wherein the expression efficiency of the construct is higher than the expression efficiency of HGF cDNA or deleted variant HGF (dHGF) cDNA.
18. The method of claim 1, wherein the expression level of the construct is about 20- to 100-fold higher than the expression level of the HGF cDNA or dHGF cDNA.
19. The method of claim 1, wherein the cell is a mammalian cell, a bacterial cell or a yeast cell.
20. The method of claim 19, wherein the cell is a mammalian cell.
21. The method of claim 20, wherein the transformation of said mammalian cell is *in vivo*.

* * * * *